Sociedad Americana de Hirudoterapia

Center for Examinations and Tests in Health Service — Republic of Belarus

RCEMTH · Belarus · europe

Regulatory jurisdiction profileJurisdictional reference
Unregulatednational regulator

Belarus's Republican Center for Examinations and Tests in Health Service (Ministry of Health) — under Belarusian law leeches have been used historically in clinical and traditional practice; the exact contemporary regulatory pathway has not been independently verified by ASH.

Regulatory Profile

Agency type
national regulator
Region
europe
Country
Belarus
Leech status
unregulated
Last ASH review
2026-05-26

Relevant Regulation Codes

  • Belarusian Law on Healthcare (No. 2435-XII, as amended)
  • Belarusian Law on Circulation of Medicines (No. 161-Z)
  • Belarusian national medical device regulatory framework

Prescriber Requirements

  • Belarusian Ministry of Health–licensed physician — order required for any biomedical device application
  • Allied health professional application under physician supervision per institutional protocol

Supply Chain & GMP

RCEMTH registration as applicable; Russian and Belarusian-language labelling. Standard cold-chain conditions; cross-border movement subject to Eurasian Economic Union (EAEU) harmonisation.

Import/Export Rules

Ministry of Health import authorisation; veterinary services clearance for live invertebrates; CITES Appendix II paperwork for Hirudo medicinalis / verbana. EAEU customs procedures apply.

Reimbursement Context

Coverage under the public healthcare system varies by setting; outpatient hirudotherapy is generally not separately reimbursed.

ASH Editorial Notes

Leech-specific pathway not independently verified by ASH; in practice Belarus shares regulatory conventions with Russia (Roszdravnadzor) under the EAEU framework. Hirudotherapy has historical clinical recognition in the post-Soviet space; the exact statutory pathway has not been independently mapped by ASH.

Related Jurisdictions

Este sitio web proporciona información educativa y no constituye consejo médico, diagnóstico ni recomendaciones de tratamiento. La terapia con sanguijuelas medicinales conlleva riesgos clínicamente significativos y debe ser realizada únicamente por profesionales calificados bajo protocolos aprobados institucionalmente. La autorización 510(k) de la FDA para sanguijuelas medicinales se limita a indicaciones específicas; las discusiones sobre uso investigativo y fuera de indicación se señalan correspondientemente. Para orientación médica específica, consulte a un profesional de salud calificado.